Workflow
曼海姆硫酸钾
icon
Search documents
红四方: 红四方2025年第三次临时股东会会议资料
Zheng Quan Zhi Xing· 2025-09-02 16:15
Core Viewpoint - The company is convening its third extraordinary general meeting of shareholders in 2025 to discuss and vote on important matters, including changes to its business scope and amendments to its articles of association [1][9]. Meeting Details - The meeting is scheduled for September 10, 2025, at 14:30, located at the conference room on the seventh floor of the Xinda Center, Hefei, Anhui Province [5]. - Voting will be conducted through a combination of on-site and online methods, with specific time slots for online voting [5]. Shareholder Rights and Responsibilities - Shareholders have the right to speak, inquire, and vote during the meeting, and must register to verify their qualifications [2][3]. - The company emphasizes the importance of maintaining order and protecting the rights of all shareholders during the meeting [2][3]. Agenda and Proposals - The agenda includes the election of vote counters, the reading of meeting guidelines, and the discussion of specific proposals [5]. - A key proposal involves changing the company's business scope to include the production and operation of hazardous chemicals, necessitated by the completion of a new production facility [6][9]. Business Scope Changes - The company plans to amend its business scope to include "production and operation of hazardous chemicals," reflecting its operational needs following the establishment of a new production line for potassium sulfate and calcium chloride [6][7]. - The previous business scope included fertilizer production and sales, while the new scope will expand to include hazardous chemical production and sales [7][8]. Articles of Association Amendments - Amendments to the articles of association will be made to align with the new business scope, specifically adding provisions for hazardous chemical production and operation [8][9]. - The board of directors has approved the proposal, which will be submitted for shareholder approval [9].